CEL-SCI Corporation (CVM)
Develops immunotherapy drugs that train the immune system to fight cancer and infections.
$1.20+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-87.3%
The outlook
CEL-SCI is trading near its 52-week low, well below both its 50- and 200-day moving averages, reflecting a weak near-term trend. The single analyst covering the stock rates it a Buy with an average price target roughly 11.5× the current price, though coverage is minimal. Overall, the data shows a highly depressed stock with a bullish outlier view, but limited analyst support.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 1 analysts
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +1150% vs current price
Market cap
$21.0M
52-wk high
$13.48
52-wk low
$0.89
50-day avg
$1.26
200-day avg
$4.31
Trailing P/E
—